1,632-Day Compliance Journey Ends: FF’s Jia Yueting Escapes Accountability—Is It a Rebirth or a Final Gamble?

Tencent Music’s Dilemma: When Nostalgia Loses to Dopamine, How Does Soda MusicManage to “Steal the Show”?

Silicon Valley Bigwigs Warn: Companies Enforcing 996 Are Doomed as AI Boosts Efficiency a Hundredfold

2025 Net Profit Plummets, 2026 Must Win: Li Auto Has Ideals, Betting on Embodied Intelligence

Tech Evening News (Jan 14): US Approves NVIDIA H200 Exports to China; Huawei Accelerates “De-NVIDIA” Strategy; Apple & Google Ink Deep Gemini Integration Deal; Grok Enters the Pentagon.

Here’s a polished English translation of the Chinese title: **Long-Term Follow-Up Results of CARsgen’s舒瑞基奥仑赛 Injection for First-Line Sequential Treatment of Gastric Cancer Presented at the 2026 ASCO Annual Meeting** Alternatively, if you’d like a more concise and natural-sounding version: **Long-Term Follow-Up Results of CARsgen’s CT041 (舒瑞基奥仑赛) for First-Line Sequential Therapy in Gastric Cancer Unveiled at 2026 ASCO** Note: “舒瑞基奥仑赛” is likely the Chinese brand name for CT041 (a CAR-T therapy targeting Claudin18.2). If you prefer to keep the original name in the translation, you can use “舒瑞基奥仑赛 Injection” or simply “舒瑞基奥仑赛” with a brief explanation.